Degludec/Liraglutide combination assessed for Time in Range, inflammation, and endothelial function in hospitalized T2DM
Background
Type 2 Diabetes Mellitus (T2DM) in hospitalized patients is a complex condition, often exacerbated by acute illness, leading to significant hyperglycemia and increased glycemic variability. This unstable glucose control is a known driver of systemic inflammation and endothelial dysfunction, which can worsen patient outcomes, prolong hospital stays, and elevate intra-hospital mortality rates. Current standard-of-care often relies on intensive basal-bolus insulin regimens, which, while effective, can be challenging to titrate, require multiple injections, and may not fully mitigate the inflammatory and vascular consequences of T2DM. The fixed-ratio combination of Insulin Degludec/Liraglutide (IDegLira) integrates a long-acting basal insulin with a GLP-1 receptor agonist, offering a potentially more stable and comprehensive approach to glycemic management, with known pleiotropic benefits on cardiovascular health and inflammation that extend beyond simple glucose lowering. This trial sought to determine if this combination could offer superior benefits in this vulnerable inpatient population.
Study Design
This randomized, double-treatment clinical trial (NCT05360537), conducted by the University of Palermo, enrolled an actual total of 100 hospitalized patients diagnosed with Type 2 Diabetes Mellitus. Participants were randomly assigned to one of two treatment arms. The experimental arm received daily administration of Insulin Degludec/Liraglutide (IDegLira), potentially alongside other oral antidiabetic agents like metformin, repaglinide, or sulfonylureas as clinically indicated. The active comparator arm received a conventional basal-bolus insulin regimen, consisting of a single daily administration of Insulin Glargine combined with three daily administrations of Aspart Insulin. The primary objectives were to compare the effects of these regimens on glycemic variability, specifically Time in Range (TIR) as assessed by continuous glucose monitoring, as well as changes in serum markers of inflammation and endothelial dysfunction. The study also explored a potential correlation between the chosen treatment and intra-hospital mortality rates.
Why It Matters
Should this trial demonstrate that Insulin Degludec/Liraglutide (IDegLira) significantly improves Time in Range while simultaneously reducing markers of inflammation and endothelial dysfunction compared to a traditional basal-bolus regimen in hospitalized Type 2 Diabetes patients, it would represent a substantial advancement in inpatient diabetes care. This could lead to a paradigm shift in managing acute hyperglycemia in hospitals, offering a more simplified, yet potentially more effective, single-injection strategy that addresses not only glucose control but also critical underlying pathologies. For clinicians, adopting IDegLira could streamline medication administration, potentially reduce the burden of multiple daily injections, and improve patient adherence, ultimately translating to better clinical outcomes, fewer complications, and potentially lower intra-hospital mortality. This would provide a compelling alternative to complex insulin titration protocols, enhancing both patient safety and resource utilization.